IMMUNE INTERFERON AND METHOD FOR ITS PURIFICATION

Abstract: An intact human immune interferon protein and a meth­ od for its extraction and purification is disclosed. This meth­ od permits the purification to homogeneity of intact recom­ binant human immune interferon using extraction of trans­ formed microorganisms containing the interferon with a protease inhibitor, such as guanidine-HCl, and purification with monoclonal antibodies to immune interferon.

Description: Immune interferon and method for its purification The present invention relates to human immune interferon having the following amino acid sequence: Cys Tyr Cys Gln Asp Pro Tyr Val Lys Glu Ala Glu Asn Leu Lys Lys Tyr Phe Asn Ala Gly His Ser Asp Val Ala Asp Asn Gly Thr Leu Phe Leu Gly Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp Arg Lys Ile Met Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Phe Lys Asn Phe Lys Asp Asp Gln Ser Ile Gln Lys Ser Val Glu Thr Ile Lys Glu Asp Met Asn Val Lys Phe Phe Asn Ser Asn Lys Lys Lys Arg Asp Asp Phe Glu Lys Leu Thr Asn Tyr Ser Val Thr Asp Leu Asn Val Gln Arg Lys Ala Ile His Glu Leu Ile Gln Val Met Ala Glu Leu Ser Pro Ala Ala Lys Thr Gly Lys Arg Lys Arg Ser <RTI ID=1.8> Gln Met Leu Phe Arg Gly Arg Arg Ala Ser Gln which sequence may optionally contain an additional methionine residue at the amino terminus, essentially free of proteolytic fragments thereof and to pharmaceutical compositions containing such human immune interferon. The invention also relates to a process for producing intact human immune interferon essentially free of proteolytic fragments thereof which process comprises extracting the intact recombinant human immune interferon from transformed microorganisms containing the same with an anti-proteolytic reagent. such as guanidine-HCl, which inhibits protease or enzyme activity but does not affect the biological activity of the immune interferon and purifying the resulting extracted interferon using novel mono clonal antibodies to immune interferon. Brief DescriPtion of the Figures Figure 1 illustrates sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of purified recombinant human immune interferon under reducing condition (A: 0.7M s-mercaptoethanol) and non-reducing condition (B). Figure 2 illustrates the comparison between the predicted amino acid sequence of recombinant human immune interferon and the actual DNA sequence of the 15K and 18K rIFN-y species. Figure 3 illustrates the HPLC separation of C-terminal peptides of 15K and 18K rIFN-y after CNBr treatment. Figure 4 represents a tryptic peptide map of 18K rIFN-y. The prior art has devised various methods for effecting the extraction and purification of the family of anti-viral proteins known as interferon. To date there are three known major classes of interferon: IFN-a (leukocyte). IFN-ss (fibroblast) and IFN-y (immune). Although the various interferon classes may be related in terms of antiviral. anti-proliferative or structural arrangement, the prior art has had so far been unable to devise a uniform method for the extraction and purification of all of these classes. Indeed. many of the processes useful for the extraction and purification of leukocyte interferon from a crude mixture of other proteins and cell debris would not work to extract and purify fibroblast or immune interferon from the same kind of preparation. The extraction step in the purification processes of the prior art typically involved either the mechanical (i.e. sonification) or chemical lysis of microorganisms which have produced, often through recombinant techniques, the desired foreign protein. However, during this mechanical or chemical lysis procedure various cellular proteases are also released into the mixture. These proteases are then free to enzymatically act upon and degrade the foreign protein in the mixture. These proteases can, therefore, hinder or inhibit the purification to homogeneity of the complete or mature and biologically active form of the "foreign" protein. It is, therefore, an object of the present invention to provide a method which overcomes the limitations of the prior art extraction and purification techniques whereby the intact sequence form of immune interferon is obtained and whereby fragments from proteolytic degradation are eliminated from the purified immune interferon. preparation. It is further an object of the present invention to obtain a homogeneous and intact form of immune interferon. DescriPtion of the Preferred Embodiments It has now been discovered in the case of immune interferon, that extraction and purification with any of the conventional techniques described in the prior art will not yield an entirely homogeneous preparation of immune interferon with an intact or complete amino acid sequence. Only recently has recombinant technology advanced to the point at which it is possible to obtain sufficient quantities of rIFN-y so as to characterize it and determine its amino acid sequence. When conventional prior art techniques were utilized to extract rIFN- preparations and the amino acid sequence of purified material was determined, it was discovered that the purified preparation was, in fact, comprised of a variety of related protein species of different molecular weight. It has further now been discovered by amino acid sequencing that these protein species are actually the intact sequence form of immune interferon in combination with a majority of fragments of the intact sequence protein. Surprisingly, even though it has now been discovered that the prior art mixture contained both intact immune interferon protein and fragments thereof, it has been discovered that apparently a component of this mixture has also retained biological activity. The extraction of rIFN-y can be carried out with the use of sonification or chemical lysis. However, the rIFN-y (the DNA base sequence and amino acid sequence reduced therefrom of which is described in reference 1) is degraded during the sonification or chemical lysis extraction step. Sonification of frozen cells, however, yielded primarily 15K rIFN-y, i.e., rIFN-y with removal of C-terminal amino acid residues Nos. 132-146. This degradation can be prevented by use of a reagent for extraction, such as guanidine-HCl1 which does not affect the biological activity or amino acid sequence of the rIFN-y under the conditions of extraction. Additionally, it has surprisingly been found that immune interferon retains its biological activity after a guanidine-HCl extraction step even though guanidine-HCl destroys the biological activity when added to a purified preparation of immune interferon. This invention, therefore, comprises an intact and complete sequence form of recombinant human immune interferon. This protein is obtained from a preparation of transformed microorganisms containing it by treating the transformed microorganisms with a reagent (or mixture of reagents), such as guanidine-HCl, a protein denaturing agent, which, it is believed, inhibits protease or enzyme activity during extraction but which does not affect the activity of the desired protein under the conditions of extraction. Purified rIFN-y is finally obtained by applying the extraction supernatant, preferably after appropriate dilution, directly on a purification means, preferably a monoclonal antibody column. These extraction and purification processes can be automated for large-scale production. Thus, the invention makes possible for the first time the availability of large amounts of homogeneous rIFN-y and thus will permit extensive clinical trials, biological studies, X-ray crystallography and structure-function studies. The anti-proteolytic agent of this invention may be any guanidinium salt. Among such guanidinium salts there are salts with organic acids such as, for example,acetic acid, or with mineral acids, such as1 four example,the hydrohalides, i.e. hydrobromide, hydrochloride, hydrofluoride and hydroiodide. The preferred guanidinium salt is guanidine hydrochloride. The concentration of guanidinium salt in the treatment of the microorganisms is not critical in that any effective amount may be used. It is preferred, however, that a 3 to 7M solution of the guanidinium salt be used for treating the microorganisms and that about 3 to 9 volumes of the salt solution be used per gram of transformed microorganisms. The concentration of the salt may be achieved by making the salt up in a solvent such as water or aqueous buffers, such as ammonium acetate, pyridine/acetic aci, and the like. It is also foreseeable that in the practice of this invention other protease inhibitor reagents may be used, such as urea and thiocyanate. Further preferred embodiments will be illustrated in the following specification and examples. Recombinant human immune interferon produced in E. coli is preferably extracted from frozen cell paste by 7M guanidine-HCl and purified by purification means preferably with a novel monoclonal antibody affinity column. The purified interferon with an apparent M.W. of 18,000 daltons (18K) by SDS-PAGE has been obtained with guanidine, whereas lower M.W. species (major species about 15,000 daltons, 15K) were isolated by sonification in the absence of guanidine extraction. The amino terminal sequences of both the 18K and 15K proteins were consistent with the sequence predicted from the DNA coding for this human immune interferon protein. The DNA sequence of 18K immune interferon as used throughout this specification has the following formula: X AGGAGGAATTC ATG TGT TAC TGC CAG GAC CCA TAT GTA AAA GAA GCA GAA AAC CTT AAG AAA TAT TTT AAT GCA GGT CAT TCA GAT GTA GCG GAT AAT GGA ACT CTT TTC TTA GGC ATT TTG AAG AAT TGG AAA GAG GAG AGT GAC AGA AAA ATA ATG CAG AGC CAA ATT GTC TCC TTT TAC TTC AAA CTT TTT AAA AAC TTT AAA GAT GAC CAG AGC ATC CAA AAG AGT GTG GAG ACC ATC AAG GAA GAC ATG AAT GTC AAG TTT TTC AAT AGC AAC AAA AAG AAA CGA GAT GAC TTC GAA AAG CTG ACT AAT TAT TCG GTA ACT GAC TTG AAT GTC CAA CGC AAA GCA ATA CAT GAA CTC ATC CAA GTG ATG GCT GAA CTG TCG CCA GCA GCT AAA ACA GGG AAG CGA AAA AGG AGT CAG ATG CTG TTT CGA GGT CGA AGA GCA TCC CAG TAA y wherein the nucleotides under the "X" code for the ribosome binding site and translational start signal, the nucleotides over "Y" code for the translational stop signal. The C-terminal sequence which was determined by analyzing and sequencing purified C-terminal peptide released from the 18K rIFN-y matched with the predicted amino acid sequence of rIFN-y indicating that the 18K species is the intact molecule. The amino acid sequence of 18K immune interferon as used throughout this specification has the following formula: : Cys Tyr Cys Gln Asp Pro Tyr Val Lys Glu Ala Glu Asn Leu Lys Lys Tyr Phe Asn Ala Gly His Ser Asp Val Ala Asp Asn Gly Thr Leu Phe Leu Gly Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp Arg Lys Ile Met Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Phe Lys Asn Phe Lys Asp Asp Gln Ser Ile Gln Lys Ser Val Glu Thr Ile Lys Glu Asp Met Asn Val Lys Phe Phe Asn Ser Asn Lys Lys Lys Arg Asp Asp Phe Glu Lys Leu Thr Asn Tyr Ser Val Thr Asp Leu Asn Val Gln Arg Lys Ala Ile His Glu Leu Ile Gln Val Met Ala Glu Leu Ser Pro Ala Ala Lys Thr Gly Lys Arg Lys Arg Ser Gln met Leu Phe Arg Gly Arg Arg Ala Ser Gln It is also within the contemplation of this invention that the amino terminus of the immune interferon protein is characterized by an additional methionine (Met) residue. Thus intact 18K rIFN-y comprises the polypeptides starting with either methionine or cysteine at the amino terminus and mixtures thereof. In a preferred embodiment of this invention, the microorganism employed as the recipient in the fermentation procedures and unless otherwise noted, is the microorganism Escherichia coli K-12 strain 294 as described in British Patent Publication No. 2055382A which has been deposited with the American Type Culture Collection under ATCC Accession No. 31446 on October 28, 1978. Furthermore, all recombinant DNA work herein was performed in compliance with applicable guidelines of the National Institutes of Health. The invention, however, includes the use not only of E. coli K-12 strain 294, mentioned above, but also of other known E. coli strains such as E. coli MA210 or E. coli RR1 (ATCC No. 31343), or other microorganisms many of which are publicly available or deposited and available from recogni zed microorganism depository institutions, such as the American Type Culture Collection (see e.g. the ATCC catalogue). In accordance with this invention the aforementioned novel immune interferon can be used for the same purposes as the other known interferons, e.g. in the prophylaxis or treatment of viral or neoplastic disorders or in the treatment of immunosupressive conditions. It may be administered in pharmaceutically acceptable oral, injectable or topical compositions and modes. Dosages and dose rates may parallel those currently being used in clinical applications of the known interferons, typically about 1-200 x 106 units daily. These pharmaceutical compositions of the invention contain said immune interferon in association with a compatible pharmaceutically acceptable carrier material. Any conventional carrier material can be utilized. The carrier material can be an organic or inorganic inert carrier material suitable for enteral, percutaneous or parenteral administration. Suitable carriers include water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc. vegetable oils, polyalkylene-glycols, petroleum jelly and the like. Furthermore, the pharmaceutical preparations may contain other pharmaceutically active agents. Additional additives such as flavoring agents, preservatives, stabilizers, emulsifying agents, buffers and the like may be added in accordance with accepted practices of pharmaceutical compounding. The pharmaceutical preparations can be made up in any conventional form including: a) a solid form for oral administration such as tablets, capsules, pills, powders, granules, and the like: b) a liquid form for oral administration such as solutions, syrups, suspensions, elixirs and the like: c) preparations for parenteral administration such as sterile solutions, suspensions or emulsions: and d) preparations for topical administrations such as solutions, suspensions, ointments, creams, gels, micronized powders, aerosols and the like. The pharmaceutical preparations may be sterilized and/or may contain adjuvants such as preservatives, stabilizers, wetting agents, emulsifiers, salts for varying the osmotic pressure and/or buffers. Parenteral dosage forms may be infusions or injectable solutions which can be injected intravenously or intramuscularly. These preparations can also contain other medicinally active substances. Additional additives such as preservatives, stabilizers, emulsifying agents, buffers and the like may be added in accordance with accepted practices of pharmaceutical compounding. ExamPle 1 Synthesis of carrier Protein-polypeptide comPlex used as antigen The polypeptide H-Lys-Arg-Lys-Arg-Ser-Gln-Met-Leu-Phe- Arg-Gly-Arg-Arg-Ala-Ser-Gln-OH was coupled with thyroglobulin (hereinafter TG) according to the method of Goodfriend et al., Science 144, 1334 (1964). The peptide itself can be produced by conventional methods of peptide synthesis. Either of the solid phase and liquid phase method may be used, although the liquid phase synthetic method is advantageous in many cases. Such methods of peptide synthesis are described, for example, by Schröder and Lübte in "The Peptides", Vol. 1, Academic Press, New York, USA., 1966, or by Izumiya et al. in "Peptide Syntheses", Maruzen, Tokyo, Japan, 1975, or by Haruaki Yajima in "Experiments in Biochemistry", Vol. 1, pages 207-400, Tokyo Kagaku Dojin, 1977, and include, among others, the azide method, chloride method, acid anhydride method, mixed acid anhydride method, DCC method, active ester method, method using Woodward reagent K, carbodiimidazole method, oxidation-reduction method and DCC/additive (e.g. HONB, HOBt, HOSu) method. For a detailed description of the preparation of the 131-146 fragment of IFN-y see published European patent application No. 103 898. 2.5 mg of said polypeptide were mixed with 3.75 mg of TG and, following addition of 2 ml of 50 mM phosphate buffer1 the mixture was stirred well in ice water. Thereto was gradually added drop by drop a solution of 30.4 mg of carbodiimide hydrochloride in 200 ml of distilled water. Thereafter, the mixture was stirred in ice water for 3 hours. After completion of the reaction, dialysis was performed against distilled water to a sufficient extent, followed by lyophilization to give 4.7 mg of a protein complex. ExamPle 2 PrePartion of enzyme-linked antigen for Enzyme Immunoassay (EIA) for antibody detection The enzyme-linked antigen for EIA was prepared according to Kitagawa et al., Journal of Biochemistry 79, 233 (1976). (i) Introduction of a maleimido group into the polypeptide The polypeptide (350 nmoles) as obtained in Example 1 was dissolved in 1 ml of 100 mM phosphate buffer (pH 6.8), and the solution was added to a solution of 585 Bg (1.75 trmoles) of N-(4-carboxycyclohexylmethyl)maleimide N-hydroxy-succinimide ester in 70 > 1 of N,N-dimethylformamide. The mixture was stirred at 300 for 30 minutes. After completion of the reaction, fractionation was performed using a Sephadex G-25 column to give 185 nmoles of a polypeptide fraction with the maleimido group introduced therein. (ii) Coupling of the maleimido-group-containing polypeptide with ss-D-galactosidase The maleimido-containing polypeptide (16.5 nmoles) was mixed with 3.3 nmoles of ss-D-galactosidase. After 18 hours of reaction at 40C, 412,5 nmoles of ss-mercaptoethanol were added to terminate the reaction. The ss-D-galactosidase-- coupled polypeptide was fractionated on a Sepharose 6B column and used for the subsequent experiments. ExamPle 3 Immunization Each of 6 female BALB/C mice aged 7 to 8 weeks was subcutaneously inoculated with 40 Bg (on the basis of the protein) of the protein complex obtained in Example 1 as antigen in intimate admixture with Freund's complete adjuvant (primary immunization). Two weeks after the primary immunization, the mice were again subcutaneously inoculated with the antigen at the same dose as above in intimate admixture with Freund's incomplete adjuvant (secondary immunization). Further two weeks later, a third immunization was made in the same manner as in the secondary immunization. Six days after the third immunization, partial blood sampling was made from the mice and the serum antibody titers were determined by the EIA method described below (compare Immunopharmacology 1, 3 (1978]). The mouse numbered y-2 gave the highest antibody titer and was subjected to a final immunization by intravenous inoculation with 120 iig of the antigen dissolved in 0.5 ml of aqueous sodium chloride. The antibody titer data for each mouse are shown in Table 1. Table 1 Antipeptide antibody titers in immunized mice EMI12.1 <tb> <SEP> B/T <SEP> (%) <tb> Mouse <SEP> No. <SEP> Primary <SEP> immu- <SEP> Secondary <SEP> Third <SEP> immu <tb> <SEP> nization <SEP> 1) <SEP> immunization <SEP> 2) <SEP> nization <SEP> 3) <tb> <SEP> y-l <SEP> - <SEP> 4) <SEP> N.D. <SEP> 24.5 <tb> <SEP> 2 <SEP> N.D. <SEP> 5) <SEP> 19.3 <SEP> 35.3 <tb> <SEP> 3 <SEP> - <SEP> N.D. <SEP> 24.7 <tb> <SEP> 4 <SEP> N.D. <SEP> 1.3 <SEP> 1.7 <tb> <SEP> 5 <SEP> N.D. <SEP> 1.8 <SEP> 5.0 <tb> <SEP> 6 <SEP> - <SEP> N.D. <SEP> 0.8 <tb> Normal <tb> mouse <SEP> 0.6 <SEP> 0.1 <SEP> N.D. <tb> 1) Serum dilution ratio: 1/1000 2) Serum dilution ratio: 1/6300 3) Serum dilution ratio: 1/7800 4) -: Not detectable 5) N.D.: Not determined B/T: (Bound enzyme activity/total added enzyme activity) x 100 EIA method The detection of antibody activity in the serum of mice immunized with the protein complex obtained in Example 2 or in the hybridoma supernatant was conducted by the EIA method (Immunology 1, 3 (1978)]. Thus, the serum or hybridoma supernatant was diluted with buffer A (20 mM Na2HPO4, 100 mM Nail, 0.1% NaN3, 1 mM MgCl2, pH 7.0), a 100- > 1 portion of the dilution was mixed with 100 > 1 of the enzyme-linked polypeptide derivative (Example 2) and the reaction was allowed to proceed at 240C for 24 hours. Thereafter, 100 > 1 of 3% cellulose coupled with rabbit anti-mouse IgG was added, and the reaction was allowed to proceed at 240C for 4 hours. After completion of the reaction, the cellulose was washed well with buffer A containing 0.5% of Tween 20, then 500 > 1 of 20 Bg/ml 4-methylumbelliferyl-R-D-galactoside was added and, after 2 hours of reaction at 370C, 3 ml of 100 mM carbonate buffer (pH 10.5) were added to terminate the reaction. The fluorescence intensity was measured with a fluorometer (excitation: 365 nm; emission: 450 nm). ExamPle 4 Cell fusion Three days after the final immunization as described in Example 3, the spleen was excised from the y-2 mouse, filtered under pressure through a stainless mesh, and suspended in Eagle's minimum essential medium (MEM) to give a spleen cell suspension. For cell fusion, BALB/C mouse-derived P3-x63.Ag8.Ul (P3U1) myeloma cells were used (Current Topics in Microbiology and Immunology, 81, 1 (1978)]. Cell fusion was performed by the original method of Kbhler and Milstein, Nature 256, 495-497 (1975). Thus, spleen cells and P3U1 cells were separately washed three times with serum-free MEM and mixed at a ratio of 5:1 (in number of cells). The mixture was centrifuged at 800 rpm for 15 minutes, whereby the cells were settled. After thorough removal of the supernatant, the sediment was lightly loosened, 0.3 ml of 45% polyethylene glycol (PEG) 6000 (Koch-Light) was added, and the mixture was allowed to stand in a warm water tank maintained at 370C for 7 minutes so as to effect cell fusion. Thereafter, MEM was added thereto at a rate of 2 ml per minute. After addition of 12 ml in total of MEM, the resulting mixture was centrifuged at 600 rpm for 15 minutes, followed by removal of the supernatant. The cell sediment was suspended in RPMI-1640 medium supplemented with 10% fetal calf serum (RPMI1640-lOFCS) in a concen tration of 2 x 105 P3U1 cells/ml and each of 144 wells on 24-well multidishes (Linbro) was seeded with 1 ml of the suspension. After seeding. the cells were incubated at 370C in a 5% carbon dioxide gas incubator. After 24 hours, HAT-selective culture was started by adding RPMI1640-lOFCS medium supplemented with HAT (1 x 10 4 M hypoxanthine, 4 x 10 7 M aminopterin, 1.6 x 10 5 M thymidine) medium in an amount of 1 ml per well. The HAT-selective culture was continued while 1 ml of the old medium was replaced by 1 ml of HAT medium 3, 5 and 7 days after start of the culture. The growth of hybridomas was noted 10 to 14 days after cell fusion. When the culture broth turned yellow (about 1 x 106 cells/ml), the supernatant was collected and examined for the presence of antibody by the EIA method. In this manner, supernatants from 141 wells in which hybridoma growth had been noted were examined. Two wells (y 2-11 and y 2-100) showed intense antibody activity and other two wells (y 2-62 and y 2-70) presented weak antibody activity. ExamPle 5 Cloning Hybridomas from 3 wells (y 2-11, y 2-62 and y 2-100) which were positive in antibody activity were cloned by the limiting dilution method. Thus, hybridoma cells were suspended in RPMI1640-20FCS in a concentration of at least 2 hybridoma cells/ml and the suspension was distributed in 0.1-ml portions into the wells on a 96-well microplate. In said distribution, 5 x 105 per well of BALB/C mouse thymocytes were added as feeder cells. As a result, cell proliferation was observed in about 2 weeks. The supernatant was then collected and examined for the presence of antibodies by the EIA method as described in Example 3. Antibody activity was noted in 8 of 19 clones from y 2-11 well, in 3 of 54 clones from y 2-62 well, and in 5 of 47 clones from y 2-100 well (Table 2). Table 2 Anti-peptide antibody activity of cloned hybridomas EMI15.1 <tb> Hybridoma <SEP> No. <SEP> B/T <SEP> (%) <tb> y <SEP> 2-11 <tb> <SEP> 1 <SEP> 68 <tb> <SEP> 2 <SEP> 31 <tb> <SEP> 3 <SEP> 63 <tb> <SEP> 6 <SEP> 68 <tb> <SEP> 7 <SEP> 67 <tb> <SEP> 9 <SEP> 69 <tb> <SEP> 12 <SEP> 42 <tb> <SEP> 18 <SEP> 60 <tb> y <SEP> 2-62 <tb> <SEP> 14 <SEP> 20 <tb> <SEP> 16 <SEP> 21 <tb> <SEP> 34 <SEP> 16 <tb> y <SEP> 2-100 <tb> <SEP> 2 <SEP> 69 <tb> <SEP> 3 <SEP> 70 <tb> <SEP> 16 <SEP> 56 <tb> <SEP> 25 <SEP> 80 <tb> <SEP> 46 <SEP> 33 <tb> Hyperimmune <SEP> mouse <SEP> serum <SEP> 35 <tb> Example 6 Binding capacity of monoclonal antibodies to IFN-y The binding capacity of monoclonal antibodies to IFN-y was determined by the following method. To 300 > 1 of a 3% solution of cellulose coupled with rabbit anti-mouse IgG antibody, 300 > 1 of the culture supernatant of each of 2 or 3 cloned cell lines from each of y 2-11. y 2-62 and y 2-100 wells was added, and the reaction was allowed to proceed at room temperature for 12 to 20 hours. Then, the cellulose was thoroughly washed with physiological saline, and 550 U/ml of IFN-y obtained by the procedure mentioned below was added thereto. After 3 to 4 hours of reaction, the supernatant was collected and the IFN-y obtained by the procedure mentioned below was added thereto. After 3 to 4 hours of reaction, the supernatant was collected and the IFN-y'activity therein was determined by the cytopathic effect (CPE) reading method using a microplate (Applied Microbiology 16, 1706 (1968)]. Thus, 50 > 1 of MEM was placed in each well of a 96-well microplate and 50 > 1 of the IFN sample was added to the first well, followed by serial two-fold dilution. To each well thus prepared, 50 > 1 of a WISH cell suspension (4 x cells/ml) in 20% FCS-containing MEM was added, and incubation was conducted in a carbon dioxide gas incubator at 370C for 24 hours. Thereafter, 50 > 1 of a vesicular stomatitis virus (New Jersey strain) preparation adjusted to a concentration of 2000TCID50 (TCID50: median tissue culture infecting dose) was added to each well and incubation was performed in a carbon dioxide incubator at 370C. About 35 hours later, when cells in the IFN sample-free well showed 100% CPE, each well was microscopically observed for the estimation of CPE, and the reciprocal of the dilution factor for the IFN sample in that well in which 50% CPE was noted was referred to as the IFN titer. The IFN-y sample used was the supernatant collected 72 hours after stimulation of human peripheral lymphocytes with 40 Bg/ml of concanavalin A and 15 ng/ml of 12-O-tetra-decanoylphorbol-13-acetate. Each ml of this culture supernatant contained 4400 units of human IFN-y (heat and acid labile). If antibodies having binding capacity to IFN-y are present in the cloned cell culture supernatant, then the added IFN-y should bind to the antibodies on cellulose and reduction in IFN-y activity of the supernatant should occur. As a result, for the clone y 2-11, relatively intense binding activity to IFN-y was noted and 50-75% of the added IFN-y (550 U/ml) was bound to antibodies (Table 3). Table 3 Absorption of IFN-y activity by monoclonal antibodies EMI17.1 <tb> Hybridoma <SEP> culture <SEP> Residual <SEP> IFN <SEP> activity <tb> <SEP> U <SEP> ml <SEP> <tb> <SEP> Experiment <SEP> Experiment <tb> <SEP> 1 <SEP> 2 <tb> <SEP> y <SEP> 2-11.1 <SEP> 138 <SEP> 275 <tb> <SEP> y <SEP> 2-11.2 <SEP> 207 <SEP> N.D. <tb> <SEP> y <SEP> 2-11.6 <SEP> N.D. <SEP> 275 <tb> <SEP> y <SEP> 2-62.2 <SEP> 275 <SEP> 550 <tb> <SEP> y <SEP> 2-62.3 <SEP> 275 <SEP> 550 <tb> <SEP> y <SEP> 2-100.2 <SEP> 550 <SEP> N.D. <tb> <SEP> y <SEP> 2-100.3 <SEP> 550 <SEP> N.D. <tb> <SEP> 550 <SEP> 550 <tb> Example 7 Ascites formation by monoclonal antibody-producing hybridomas Ascites formation was caused by intraperitoneal inoculation of BALB/c mice intraperitoneally pretreated with 6 0.5 ml of mineral oil with 1 x 10 y 2-11.1 clone cells capable of producing antibodies having IFN-y-binding activity. Ten days after intraperitoneal administration of hybridomas, the ascitic fluid was taken and examined for antibody activity up to 107-fold dilution. While the antibody activity of the corresponding clone cell culture supernatant was detected up to 104-fold dilution, the formation of ascites (ascitization) led to an about 1000 times increase in antibody activity. Example 8 Monoclonal antibody purification Using 4 ml of the ascitic fluid obtained in Example 7 as the starting material, monoclonal antibody purification was performed by the method of Staehelin et al. (Journal of Biological Chemistry 256, 9750, [1981]). Thus, the ascitic fluid was first centrifuged at 10,000 rpm for 15 minutes to remove fibrin-like substances therefrom and was then diluted with phosphate buffer-saline (PBS: 8.1 mM NaH2PO4, 1.5 mM KH2PO4, 2.7 mM KC1, 137 mM NaCi; pH 7.2) to a concentration at which the ultraviolet absorption at 280 nm (A280) would range from 12 to 14. Thereafter, saturated aqueous ammonium sulfate was added to the diluted sample to a sulfate concentration of 47%. The mixture was stirred at 40C for 60 minutes to effect salting out and was then centrifuged (10,000 rpm, 15 minutes) to give a precipitate. The precipitate was dissolved in 20 mM Tris buffer (pH 7.9) containing 50 mM NaCl and dialyzed against 2 liters of the same buffer. Two hours later, the dialyzing solution was replaced by a fresh 2-liter portion of the same solution and the dialysis was continued for further 15 hours. Thereafter, the precipitate was removed by centrifugation at 10,000 rpm for 15 minutes, and the supernatant was adjusted to a concentration such that the A280 value became 20-30. This sample was subjected to fractionation on a DEAE-cellulose column (8 ml, Whatman DE52) equilibrated with a sufficient amount of Tris buffer (pH 7.9) containing 50 mM Nail, elution being made with Tris buffer containing 50 mM NaCl at a flow rate of 1.5 ml/minutes. Under these conditions, the antibody activity was detected mainly in effluent fractions. Confirmation that the purified sample is antibody was made by the SDS-PAGE method as described by Laemmli et al., Nature 227, 680 (1970). Thus, some of the fractions obtained by ammonium sulfate salting out and DEAE-cellulose fractionation were each subjected to reduction with 2-mercaptoethanol, followed by 17% SDS gel electrophoresis at 30 volts for 24 hours. In agreement with the antibody activity peaks, two bands were noted at positions corresponding to molecular weights of about 55 kilodaltons (H chain) and about 28 kilodaltons (L chain). The thus-purified antibody fraction 17 was examined for IFN-y-binding activity by adding IFN-y (2200 U/ml). It was thus found that about 50% of IFN-y was bound to the antibody (Table 4). Table 4 EMI19.1 <tb> <SEP> Sample <SEP> Dilution <SEP> Residual <SEP> IFN <SEP> activity <SEP> (U/ <tb> &gamma; <SEP> 2-11.1 <SEP> fraction <SEP> 17 <SEP> 10-1 <SEP> 1100 <tb> <SEP> 10-2 <SEP> 1100 <tb> <SEP> 10-3 <SEP> 2200 <SEP> <tb> <SEP> 2200 <SEP> <tb> EMI20.1 <tb> Anti-IgE <SEP> monoclonal <SEP> 10-1 <SEP> 2200 <tb> antibody <SEP> 10-2 <SEP> 2200 <tb> <SEP> 2200 <SEP> <tb> <SEP> 2200 <SEP> <tb> Example 9 Subclass to which monoclonal antibodies belong Purified antibody fraction 17 (Example 8) was diluted 10 times and subjected to immuno-precipitation reaction in agar (Ouchterlony test: Immunological Methods, Gel-Diffusion Techniques, Blackwell, Oxford, 1964) using goat anti-mouse IgGl, G2a, G2b and G3 antibodies (Miles) so that the IgG subclass to which y 2-11.1 monoclonal antibodies might belong could be identified. A single distinct band was found between the monoclonal antibody and the goat anti-mouse IgG2b antibody, while no band formation was noted between the monoclonal antibody and other anti-antibodies. Accordingly, said monoclonal antibody was found to belong to IgG2b (Table 5). Table 5 Monoclonal antibody subclass EMI20.2 <tb> <SEP> Antigen <SEP> Antibody <SEP> Precipitation <tb> <SEP> curve <tb> Monoclonal <SEP> antibody <SEP> of <SEP> the <tb> present <SEP> invention <tb> (fraction <SEP> 17) <SEP> Anti-IgGl <SEP> - <SEP> <tb> <SEP> ,. <SEP> Anti-IgG2a <SEP> <tb> <SEP> Anti-IgG2b <SEP> + <tb> <SEP> " <SEP> Anti-IgG3 <SEP> - <SEP> <tb> ExamPle 10 Twenty-five ml (65.3 mg) of the monoclonal antibody from the effluent fractions as purified by the procedure of Example 8 was dialyzed overnight against 0.1M NaHCO3 (pH 8.3). Separately, 25 ml of AFFI-GEL 10 (Bio-Rad) was thoroughly washed with water using a glass filter, suspended in 0.1M NaHCO3 (pH 8.3) and mixed with the above antibody. The mixture was stirred gently at 40C for 4 hours to effect the reaction, and then allowed to stand at 40C overnight. The AFFI-GEL 10 was washed well with 0.1M NaHCO3 (pH 8.3) using a glass filter. To the gel were added 25 ml of a solution (pH 8.0) containing 0.1M ethanolamine and 0.15M Nazi. The mixture was shaken at 40C for an hour so as to block possibly remaining unreacted active groups. Then, the gel was washed well with PBS, and suspended in 25 ml of 0.1% NaN3-containing PBS. The suspension was stored at 40C. Based on the amount of the added antibody and the amount of the antibody in the recovered filtrate, it was found that the antibody was conjugated to the gel in a proportion of 2.35 mg/ml of gel. A column was packed with the reaction product obtained in this manner and used as an antibody column. ExamPle 11 E. coli RR1 (pRK148cIts, pRC231/IFI-900) (construction of this recombinant organism is described in detail in European patent application publication No. 99084) was used for rIFN-y production. Plasmids pRK248cIts and pRC231/IF-900 contained temperature sensitive Lambda repressor and IFN-y genes respectively. Expression of rIFN-y gene was under the control of the PL promoter. Overnight cultures of E. coli RR1 (pRK248cIts, pRC231/IFI-900) were grown in LB broth at 300C. One liter of the overnight culture was diluted to 10 liters with minimal M-9 medium containing casamino acids. At logarithmic growth, the culture was shifted from 300 to 420C and continued to grow at 420C for 2-3 hours. Bacteria were harvested by centrifugation and the bacterial pellets were stored at -200C until used. All fermentations and procedures were performed in accordance with recombinant DNA guidelines of the National Institutes of Health. Monoclonal antibodies were made against synthetic 131-146 C-terminal peptide of rIFN-y in the manner described above. Monoclonal antibody Mo y 2-11.1 was used for the purification of rIFN-y. The monoclonal antibody column was prepared as described in Example 10. Carboxymethylation of rIFN-y by 14C-iodoacetic acid was carried out in the presence of 6M guanidineHC1 as described in reference (3). Excess reagent was removed by HPLC on C8 reverse-phase column. Carboxypeptidase digestion was performed in 0.2M NH4HCO3 as described in reference (4). The rIFN-y was treated with CNBr (100-fold molar excess over methionine) in 70 percent formic acid as described in reference (5). CNBr peptides were separated by HPLC on a C-18 reverse-phase column. A linear gradient of 0 to 70 percent of CH3CN in 0.1% trifluoroacetic acid was used for peptide elution. Protein or peptide samples were hydrolyzed for 20-24 hours in sealed, N2-flushed, evacuated tubes in constant boiling HC1 containing 4% thioglycolic acid. Amino acid analyses were performed using a fluorescamine amino acid analyzer as described in reference (6). An ABI (Applied Biosystem, Inc.) gas-phase sequencer 470A was used for sequence analyses of carboxymethylated proteins as described in reference (7). Samples of PTH-amino acids were identified by reverse-phase HPLC on an ultrasphere ODS column as described in reference (8). All purification steps were carried out at 40C. Frozen cells (25 g) were suspended in three volumes (75 ml) of 7M guanidine-HCl (pH 7). The mixture was stirred for 1 h and then centrifuged for 1 h at 30,000 x g. The supernatant was diluted 10-fold with Dulbecco's phosphate buffered saline (PBS) or 0.15M sodium boratebuffer (pH 9.5) and then centrifuged for 30 min. at 30,000 x g. Alternatively, frozen cells (25 g) were suspended in 1.5 volumes (37.5 ml) of 0.15M sodium borate buffer (pH 9.5) and stirred for 1 h. The mixture was sonicated 5 times for 30 seconds and then centrifuged for 1 h at 30,000 x g. The supernatants from either guanidine-HCl extraction or sonification were mixed for 1 h on a rotating shaker with 25 ml silica and prewashed with PBS. The mixture was poured onto a column and the column was washed with 20-30 column volumes of 1M Nazi. The column was then eluted with 0.5M tetramethylammonium chloride in 0.01M sodium borate buffer (pH 8.0). Interferon activity was eluted in about 200 ml and separated into 4 pools. Each pool was loaded onto a monoclonal antibody (y 2-11.1) affinity column (4 ml bed volume) equilibrated with PBS. After washing with 10 column volumes of PBS buffer, the column was eluted with either 1M guanidine-HCl or 50% ethylene glycol containing 1M NaCl and 20 mM sodium phosphate buffer (pH 7.0). Interferon activity was eluted in the first 20 ml. SDS-PAGE was performed as described by Laemmli (reference 9). Protein was determined by fluorescamine analysis with crystalline bovine serum albumin as the reference standard. Interferon activity was determined by a cytopathic effect inhibition assay with vesicular stomatitis virus and human WISH cells as reported in reference 10. All interferon titers are expressed in reference units/ml calibrated against the reference standard of partially purified human immune interferon. A summary of the extraction purification procedure is presented in Table 6 (page 27). The overall recovery was 25-32% and the purification was about 100 to 769 fold with an average specific activity of 1 x 107 units/mg. Total yield of rIFN-y was 3-4 times higher with guanidineextraction. SDS-PAGE of the last stage of purification is shown in Figure 1. The material purified from guanidine extraction showed a single band at about 18,000 daltons (18K rIFN-y) whereas the material from the sonification procedure yielded a major band at about 15,000 daltons (15K rIFN-y) and a minor band at about 17,000 daltons (Fig. 1A). On non-reducing gel, dimers and oligomers of rIFN-y were formed (Fig. 1B). The 18K rIFN-y was homogeneous and the amino acid composition was consistent with that predicted from the DNA sequence. Amino acid compositions of the 15K and 18K rIFN-y are given in Table 7. Several hundred picomoles of reduced and carboxymethylated 15K and 18K protein underwent Edman degradation in an automatic gas-phase protein/peptide sequencer. The amino acid N-terminal sequences of the first 32 and 26 residues of the 15K and 18K proteins respectively were in accord with that predicted by the DNA sequence (Fig. 2). 14C-Carboxymethylated cysteines were detected in the first and third cycles of sequence analyses. No N-terminal methionine was detected. N-terminal sequence analysis of the 18K and 15K rIFN-y demonstrated that the sequence of this area of both proteins is identical to that predicted from the DNA sequence. The C-terminal peptides have also been characterized to determine whether any deletions or changes occurred in this region. Amino acid analysis of carboxypeptidase A (CPA) digestion mixture indicated that serine and/or glutamine (C-terminal amino acids) were released from the 18K rIFN-y, whereas the 15K rIFN-y was not digested by CPA under same conditions. Since Ser-Gln is the C-terminal sequence of rIFN-y the 18K species appeared to have the intact C-terminus while the 15K species has a different C-terminal residue (Lys) which is not cleaved by CPA. The C-terminal residues predicted from the DNA sequences were further confirmed by analyzing and sequencing the C-terminal peptides after CNBr treatment. C-terminal peptides were separated on the HPLC C-18 reverse-phase column (Fig. 3), A sharp peptide peak (peak II), eluted from the early part of the gradient, was obtained from the 15K rIFN-y and this peptide was absent from the CNBr digestion mixture of the 18K rIFN-y. Amino acid analysis of this peptide indicated that this peptide has no homoserine or homoserine lactone and therefore must be the C-terminal CNBr peptide of the 15K protein. Based on amino acid analysis (Table 8), this peptide corresponded to amino acid residues No. 121-131 of IFN-y (no arginine was detectable). The sequence of the 11 amino acids was confirmed by sequence analysis (Fig. 2). In the case of 18K rIFN-y, a relatively broad peak was obtained in the early part of the elution. This peak was further separated into two peaks by a shallow gradient. The amino acid analyses indicated that the first peak is the CNBr C-terminal peptide of the 18K protein (Table 8) and the amino acid composition corresponds to amino acid residues No. 138-146. The sequence of the 9 amino acids was verified by sequence determination (Fig. 2). The C-terminal amino acid of the 15K protein was determined to be lysine. These results indicate that the 18K species was the intact rIFN-y molecule, whereas the 15K species was a proteolytic product. The peptide bond between amino acid residues No. 131 and No. 132 (Lys-Arg) was cleaved on the 15K species. Example 12 Tryptic Peptide Map of 18K rIFN-y Tryptic peptide mapping of 18K rIFN-y was performed. 18K rIFN-y (43 Bg) was digested with TPCK-trypsin (1.1 Bg, Worthington (USA)) at 370C for 18 hrs in 147 > 1 of 25mM ammonium acetate-NaOH (pH 8.0). 2-Mercaptoethanol (0.6 > 1) was added to the digestion mixture and incubation was continued for 2 hrs. To stop the reaction, 53 > 1 of 1% trifluoroacetic acid (TFA) was added. The entire digest sample was chromatographed on an Ultrasphere-octyl column (5 trm, 4.6 x 250 nm, Altex (USA)) equilibrated with 0.02% TFA-5% CH3CN. Elution was accomplished at 1.0 ml/min by a linear gradient of 5-70% CH3CN at 300C. The effluent was monitored by the fluorometric method using fluorescamine. The resulting map is given in Figure 4. Example 13 Determination of the C-terminal Amino Acid of 18K rIFN-y The C-terminal amino acid of 18K rIFN-y was determined by hydrazinolysis according to the method of Narita et al. (J. Biochem. [Tokyo] 59, 170 (1966]). 18K rIFN-y (185 Bg) was heated at 1000C for 6 hrs with anhydrous hydrazine. The lyophilized hydrazinolysate was dissolved in water and benzaldehyde was added. The mixture was shaken vigorously for 1 hr at room temperature and then centrifuged. The supernatant was lyophilized and subjected to amino acid analysis. As a result, however, no amino acid was detected. This result is consistent with the fact that the C-terminal amino acid of 18K species is glutamine. Table 6 Purification of rIFN-y Purification Total Total Specific Purifi Step Protein Activity Activity cation Yield mg units unit/mg -fold I. Guanidine extraction Supernatant 2.806 2.5x108 9x104 - 100 Silica 98 1.0x108 1x106 11 40 Monoclonal Antibody 8 0.8x108 1x107 110 32 II. Sonification Supernatant 6.136 8.0x107 1.3x104 - 100 Silica 87 4.5x107 5.2x106 400 56 Monoclonal Antibody 2 2.0x107 1.0x107 769 25 Table 7 Amino Acid Compositions of 15K and 18K rIFN-y (Residue numbers) 18K (1-146) 15K (1-131) Asp 20.9 (20) 19.9 (20) Thr 5.1 (5) 4.9 (5) Ser 9.8 (11) 6.7 (9) Glu 18.5 (18) 15.1 (16) Pro * (2) * (2) Gly 5.9 (5) 5.6 (4) Ala 8.2 (8) 7.3 (7) Cys * (2) * (2) Val 9.1 (8) 9.1 (8) Met 4.7 (4) 3.8 (3) Ile 7.2 (7) 6.6 (7) Leu 10.5 (10) 9.6 (9) Tyr 5.5 (5) 4.8 (5) Phe 10.3 (10) 8.2 (9) His 1.8 (2) 2.5 (2) Lys 19.9 (20) 16.9 (19) Arg 8.6 (8) 5.6 (3) Trp * (1) * (1) Figures in parenthesis indicate the predicted amount of residues from DNA sequence. * Values not determined. Table 8 CNBr C-terminal Peptides of 15K and 18K 15K 18K Thr 0.9 (1) Ser 1.1 (1) 0.84 (1) Glu 1.1 (1) 1.1 (1) Pro * (1) Gly 1.5 (1) 1.3 (1) Ala 2.4 (3) 1.1 (1) Leu 1.0 (1) 1.1 (1) Phe I.o (1) Lys 1.9 (2) 2.8 (3) Positions in sequence 121-131 138-146 Figures in parenthesis indicate the predicted residue number from DNA sequence. * not determined. REFERENCES 1. Gray, P.W., et al., Nature 295, 503-508 (1982) 2. Stahelin, T., et al., J. Biol. Chem. 256, 9750-9754 (1981) 3. Allen, G., Sequencing of Protein and Peptides, pp. 30-31 (1981), North-Holland Publishing Co., Amsterdam, New York 4. Amber, R.P., Methods in Enzymology 11, 436-445 (1967) 5. Wolfe, R.A. and Stein, S., Modern Methods in Pharma cology, pp. 55-77 (1982), Alan R. Liss, Inc., New York, NY. 6. Stein, S. and Brink, L., Methods in Enzymology, 79, 20-25 (1981) 7. Hewick, R.M., Hunkapillar, M.W., Hodd, L.E. and Dreyer, W.I., J. Biol. Chem. 256, 7990-7997 (1981) 8. Hawke, D., Yuan, P-M., and Shively, J.E., Anal. Bio chem. 120, 302-311 (1982) 9. Laemmli, U.K., Nature 227, 680-685 (1970) 10. Rubinstein, S., Familletti, P.C., and Pestka, S., J. Virol. 37, 755-758 (1981).

Claims: CLAIMS 1. Human immune interferon having the following amino acid sequence: Cys Tyr Cys Gln Asp Pro Tyr Val Lys Glu Ala Glu Asn Leu Lys Lys Tyr Phe Asn Ala Gly His Ser Asp Val Ala Asp Asn Gly Thr Leu Phe Leu Gly Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp Arg Lys Ile Met Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Phe Lys Asn Phe Lys Asp Asp Gln Ser Ile Gln Lys Ser Val Glu Thr Ile Lys Glu Asp Met Asn Val Lys Phe Phe Asn Ser Asn Lys Lys Lys Arg Asp Asp Phe Glu Lys Leu Thr Asn Tyr Ser Val Thr Asp Leu Asn Val Gln Arg Lys Ala Ile His Glu Leu Ile Gln Val Met Ala Glu Leu Ser Pro Ala Ala Lys Thr Gly Lys Arg Lys Arg Ser Gln Met Leu Phe Arg Gly Arg Arg Ala Ser Gln essentially free of proteolytic fragments thereof. 2. Human immune interferon as claimed in claim 1 with an additional methionine residue at the amino terminus of the amino acid sequence. 3. Human immune interferon as claimed in claim 1 or claim 2 as a homogeneous peptide. 4. Human immune interferon as claimed in any one of claims 1-3 when used as a therapeutic agent. 5. A process for producing intact recombinant human immune interferon having the following amino acid sequence: Cys Tyr Cys Gln Asp Pro Tyr Val Lys Glu Ala Glu Asn Leu Lys Lys Tyr Phe Asn Ala Gly His Ser Asp Val Ala Asp Asn Gly Thr Leu Phe Leu Gly Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp Arg Lys Ile Met Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Phe Lys Asn Phe Lys Asp Asp Gln Ser Ile Gln Lys Ser Val Glu Thr Ile Lys Glu Asp Met Asn Val Lys Phe Phe Asn Ser Asn Lys Lys Lys Arg Asp Asp Phe Glu Lys Leu Thr Asn Tyr Ser Val Thr Asp Leu Asn Val Gln Arg Lys Ala Ile His Glu Leu Ile Gln Val Met Ala Glu Leu Ser Pro Ala Ala Lys Thr Gly Lys Arg Lys Arg Ser Gln Met Leu Phe Arg Gly Arg Arg Ala Ser Gln which sequence may optionally contain an additional methionine residue at the amino terminus, essentially free of proteolytic fragments thereof from transformed microorganisms containing this protein, which process comprises extracting the intact recombinant human immune interferon from said transformed microorganisms with a protease inhibitor and purifying the resulting extracted interferon using monoclonal antibodies. 6. The process of claim 5 wherein the protease inhibitor is a guanidinium salt. 7. The process of claim 5 wherein the protease inhibitor is guanidine-HCl. 8. The process of claim 6 or claim 7 wherein the guanidinium salt is in solution. 9. The process of claim 5 wherein the transformed microorganisms are suspended in a solution of guanidine-HCl. 10. The process of claim 9 wherein the guanidine-HCl concentration of the solution is at least about 4M. 11. The process of claim 9 or claim 10 wherein there are used at least about 3 volumes of the guanidinium salt solution for every gram of transformed microorganism. 12. Pharmaceutical compositions containing as active agent human immune interferon as claimed in any one of claims 1-3 and an inert pharmaceutically acceptable carrier. CLAIMS for Austria 1. A process for producing intact recombinant human immune interferon having the following amino acid sequence: Cys Tyr Cys Gln Asp Pro Tyr Val Lys Glu Ala Glu Asn Leu Lys Lys Tyr Phe Asn Ala Gly His Ser Asp Val Ala Asp Asn Gly Thr Leu Phe Leu Gly Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp Arg Lys Ile Met Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Phe Lys Asn Phe Lys Asp Asp Gln Ser Ile Gln Lys Ser Val Glu Thr Ile Lys Glu Asp Met Asn Val Lys Phe Phe Asn Ser Asn Lys Lys Lys Arg Asp Asp Phe Glu Lys Leu Thr Asn Tyr Ser Val Thr Asp Leu Asn Val Gln Arg Lys Ala Ile His Glu Leu Ile Gln Val Met Ala Glu Leu Ser Pro Ala Ala Lys Thr Gly Lys Arg Lys Arg Ser Gln Met Leu Phe Arg Gly Arg Arg Ala Ser Gln which sequence may optionally contain an additional methionine residue at the amino terminus, essentially free of proteolytic fragments thereof from transformed microorganisms containing this protein, which process comprises extracting the intact recombinant human immune interferon from said transformed microorganisms with a protease inhibitor and purifying the resulting extracted interferon using monoclonal antibodies. 2. The process of claim 1 wherein the protease inhibitor is a guanidinium salt. 3. The process of claim 1 wherein the protease inhibitor is guanidine-HCl. 4. The process of claim 2 or claim 3 wherein the guanidinium salt is in solution. 5. The process of claim 1 wherein the transformed microorganisms are suspended in a solution of guanidine-HCl. 6. The process of claim 5 wherein the guanidine-HCl concentration of the solution is at least about 4M. 7. The process of claim 5 or claim 6 wherein there are used at least about 3 volumes of the guanidinium salt solution for every gram of transformed microorganism.

Inventors: HONDA, SUSUMU, KUNG, HSIANG-FU, SUGINO, HIROMU 458-6, KAMIGORYONAKA-MACHI
Applicants: F. HOFFMANN-LA ROCHE AG, TAKEDA CHEMICAL INDUSTRIES, LTD.
Application year: 1984
Main classification: C07K13
IPC codes: C07K16, A61P37, G01N33, A61K38, C07K14, C12R1, C12N15, C07K1, C12P21, A61P35, A61P31